Mesh-Based Protection is now Recommended for use in the new Guidelines of the Task Force of Myocardial Revascularization of the European Society of Cardiology (ESC)

TEL AVIV, Israel, September 9, 2010 - InspireMD Ltd., a medical device company engaged in the development and
commercialization of the mesh based MGuard(TM) stent systems, is proud to
report that mesh-based protection, is now recommended for use in the new
Guidelines of the Task force of Myocardial Revascularization of the European
Society of Cardiology (ESC). According to the latest European Society of
Cardiology Guidelines, published at the ESC Congress last week, "Mesh-based
protection may be considered for PCI of highly thrombotic or SVG lesions" -
it has received a class IIb recommendation.

Currently, this type of approved mesh technology is
exclusively used by InspireMD in its unique and patent pending MGuard(TM)
mesh protected coronary stent system. "We are satisfied that the InspireMD
mission and technology to improve the outcome of PCI in AMI, was acknowledged
by the ESC. In the light of the extremely positive experience gathered with
MGuard we are much honored that the ESC acknowledges the MGuard mesh
technology for thrombotic lesions. The outcome from our clinical studies in
Acute MI as well as SVG patients is very positive and we are very encouraged
by this recognition of the European Society of MGuard" stated Ofir Paz,
InspireMD's CEO.

About MGuard(TM) Coronary

MGuard(TM) presents a novel combination of a coronary stent
merged with an embolic protection specifically designed for Acute MI
patients. The embolic protection is comprised of an ultra-thin polymer mesh
sleeve that wraps the stent. The MGuard(TM) coronary stent provides permanent
embolic protection, without affecting deliverability. MGuard(TM) is CE Mark
approved. The MGuard(TM) Coronary's innovative concept has enjoyed an
enthusiastic welcome from leading interventional cardiologists around the
world.

About InspireMD

InspireMD is an innovative medical device company focusing on
the development and commercialization of its proprietary stent system
technology, MGuard(TM). The company intends to apply its technology to
develop products used in interventional cardiology and other vascular
procedures. InspireMD's mission is to utilize its proprietary technology to
make its products the industry standard for stents and to provide a superior
solution to the key clinical issues of current stenting: restenosis, embolic
showers, and late thrombosis. In addition to providing embolic protection and
minimizing arterial injury, this promising technology can be an effective and
uniform drug delivery mechanism with the help of the novel micron-level net
for next generation drug eluting stents. InspireMD intends to pursue
applications of this technology both for bare metal and drug eluting stents
in coronary, carotid and peripheral artery procedures.

    Contact details:
    www.inspire-md.com
    Jonina Ohayon
    Marketing Director
    jonina@inspire-md.com
    mobile:+972-525791120

Contact details: Jonina Ohayon, Marketing Director, jonina at inspire-md.com, mobile:+972-525791120